Uterine disorders in reproductive life: Difference between revisions

From Top Italian Scientists Journal
No edit summary
Line 60: Line 60:
Uterine fibroids are the most common benign tumors of the uterus in women of reproductive age. They can be asymptomatic, but they frequently manifest with abnormal uterine bleeding, pelvic discomfort, and challenges with fertility. Submucosal or intramural fibroids can hinder embryo implantation and potentially lead to pregnancy-related complications such as miscarriage, placenta previa, preterm labor, or postpartum hemorrhage.
Uterine fibroids are the most common benign tumors of the uterus in women of reproductive age. They can be asymptomatic, but they frequently manifest with abnormal uterine bleeding, pelvic discomfort, and challenges with fertility. Submucosal or intramural fibroids can hinder embryo implantation and potentially lead to pregnancy-related complications such as miscarriage, placenta previa, preterm labor, or postpartum hemorrhage.
The increased incidence of uterine disorders has a major clinical impact on women’s health and a very poor quality of life is often reported. Therefore, prompt diagnosis and effective management are mandatory.
The increased incidence of uterine disorders has a major clinical impact on women’s health and a very poor quality of life is often reported. Therefore, prompt diagnosis and effective management are mandatory.


==Declarations==
==Declarations==

Revision as of 09:56, 13 May 2024

Published
June 1, 2024
Title
Uterine disorders in reproductive life
Authors
Felice Petraglia, Silvia Vannuccini, Angela Gallone, Virginia Manzi, Francesco La Torre, Federico Toscano, Nicolò Buffi, Flavia Sorbi, Massimiliano Fambrini.
DOI
10.62684/********
Keywords
endometriosis; adenomyosis; uterine fibroids; uterine disorders
Downloads
Download PDF
Download PDF

Felice Petraglia, Silvia Vannuccini, Angela Gallone, Virginia Manzi, Francesco La Torre, Federico Toscano, Nicolò Buffi, Flavia Sorbi, Massimiliano Fambrini.

Obstetrics and Gynecology, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, Italy

Correspondence to:
Felice Petraglia, MD
Obstetrics and Gynecology
Department of Experimental, Clinical and Biomedical Sciences
University of Florence, Largo Brambilla 3, 50134, Florence, Italy
email: felice.petraglia@unifi.it


Abstract

The development of new medical diagnostic technologies and procedures and the drop in the birth rate observed in the last decades represent the main causes of increased incidence of uterine disorders. Endometriosis, adenomyosis and uterine fibroids are benign uterine disorders whose understanding have greatly increased and clinical management have improved in recent times. Molecular pathogenetic aspects, new imaging technologies (transvaginal ultrasound and magnetic resonance), biochemical markers, hormonal drugs, minimally invasive surgical technologies were studied for diagnosis and treatment of endometriosis, adenomyosis and uterine fibroids. Sex steroid hormones, inflammation and fibrosis are key pathogenetic mechanisms of uterine disorders. Endometriosis is characterized by endometrial cells migrating outside the uterus and implanting in the pelvis, associated with inflammation, neuroangiogenesis and fibrosis causing dysmenorrhea, pelvic pain, dysuria and dyschezia. The painful symptoms may activate central sensitization and stress responses. Adenomyosis is caused by the presence of endometrial cells within the myometrium, characterized by pelvic pain, abundant menstrual bleeding and infertility. Heavy menstrual bleeding can cause the reduction of iron reserves and consequently iron deficiency anemia. Uterine fibroids are the most common benign tumors of the uterus in women of reproductive age. They can be asymptomatic, but they frequently manifest with abnormal uterine bleeding, pelvic discomfort, and challenges with fertility. Submucosal or intramural fibroids can hinder embryo implantation and potentially lead to pregnancy-related complications such as miscarriage, placenta previa, preterm labor, or postpartum hemorrhage. The increased incidence of uterine disorders has a major clinical impact on women’s health and a very poor quality of life is often reported. Therefore, prompt diagnosis and effective management are mandatory.

Declarations

Conflict of Interest

The Authors declare that there is no conflict of interest.

References

  1. 1. Critchley, H. O. D. et al. Menstruation: science and society. American Journal of Obstetrics and Gynecology 223, 624–664 (2020).
  2. 2. Critchley, H. O. D., Maybin, J. A., Armstrong, G. M. & Williams, A. R. W. Physiology of the Endometrium and Regulation of Menstruation. Physiological Reviews 100, 1149–1179 (2020).
  3. 3. Vannuccini, S., Clemenza, S., Rossi, M. & Petraglia, F. Hormonal treatments for endometriosis: The endocrine background. Reviews in Endocrine and Metabolic Disorders 23, 333–355 (2021).
  4. 4. Capezzuoli, T. et al. Ultrasound findings in infertile women with endometriosis: evidence of concomitant uterine disorders. Gynecological Endocrinology 36, 808–812 (2020).
  5. 5. Clemenza, S., Vannuccini, S., Ruotolo, A., Capezzuoli, T. & Petraglia, F. Advances in targeting estrogen synthesis and receptors in patients with endometriosis. Expert Opinion on Investigational Drugs 31, 1227–1238 (2022).
  6. 6. Rossi, M. et al. Epigenetics, endometriosis and sex steroid receptors: An update on the epigenetic regulatory mechanisms of estrogen and progesterone receptors in patients with endometriosis. in Vitamins and Hormones vol. 122 171–191 (Elsevier, 2023).
  7. 7. Reis, F. M., Petraglia, F. & Taylor, R. N. Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. Human Reproduction Update 19, 406–418 (2013).
  8. 8. Female Reproductive Dysfunction. (Springer International Publishing, Cham, 2020). doi:10.1007/978-3-030-14782-2.
  9. 9. Agarwal, S. K. et al. Clinical diagnosis of endometriosis: a call to action. American Journal of Obstetrics and Gynecology 220, 354.e1-354.e12 (2019).
  10. 10. Vercellini, P., Viganò, P., Somigliana, E. & Fedele, L. Endometriosis: pathogenesis and treatment. Nature Reviews Endocrinology 10, 261–275 (2013).
  11. 11. Smarr, M. M., Kannan, K. & Buck Louis, G. M. Endocrine disrupting chemicals and endometriosis. Fertility and Sterility 106, 959–966 (2016).
  12. 12. Cobellis, L. High plasma concentrations of di-(2-ethylhexyl)-phthalate in women with endometriosis. Human Reproduction 18, 1512–1515 (2003).
  13. 13. Markowska, A., Antoszczak, M., Markowska, J. & Huczyński, A. The Role of Selected Dietary Factors in the Development and Course of Endometriosis. Nutrients 15, 2773 (2023).
  14. 14. Brosens, I., Puttemans, P. & Benagiano, G. Endometriosis: a life cycle approach? American Journal of Obstetrics and Gynecology 209, 307–316 (2013).
  15. 15. Clemenza, S. et al. Is primary dysmenorrhea a precursor of future endometriosis development? Gynecological Endocrinology 37, 287–293 (2021).
  16. 16. Lazzeri, L. et al. Endometriosis and Perceived Stress: Impact of Surgical and Medical Treatment. Gynecol Obstet Invest 79, 229–233 (2015).
  17. 17. Lazzeri, L. et al. Surgical treatment affects perceived stress differently in women with endometriosis: correlation with severity of pain. Fertility and Sterility 103, 433–438 (2015).
  18. 18. Reis, F. M., Coutinho, L. M., Vannuccini, S., Luisi, S. & Petraglia, F. Is Stress a Cause or a Consequence of Endometriosis? Reproductive Sciences 27, 39–45 (2020).
  19. 19. Vannuccini, S. et al. Potential influence of in utero and early neonatal exposures on the later development of endometriosis. Fertility and Sterility 105, 997–1002 (2016).
  20. 20. Rahmioglu, N. et al. The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions. Nat Genet 55, 423–436 (2023).
  21. 21. Vannuccini, S. et al. Surgical treatment of endometriosis: prognostic factors for better quality of life. Gynecological Endocrinology 35, 1010–1014 (2019).
  22. 22. Vannuccini, S. et al. Mental health, pain symptoms and systemic comorbidities in women with endometriosis: a cross-sectional study. Journal of Psychosomatic Obstetrics & Gynecology 39, 315–320 (2018).
  23. 23. Chen, H. et al. Comorbidities and Quality of Life in Women Undergoing First Surgery for Endometriosis: Differences Between Chinese and Italian Population. Reprod. Sci. 28, 2359–2366 (2021).
  24. 24. Chapron, C., Marcellin, L., Borghese, B. & Santulli, P. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol 15, 666–682 (2019).
  25. 25. Pino, I. et al. “Better late than never but never late is better”, especially in young women. A multicenter Italian study on diagnostic delay for symptomatic endometriosis. The European Journal of Contraception & Reproductive Health Care 28, 10–16 (2023).
  26. 26. Petraglia, F. et al. The modern non-invasive diagnosis of endometriosis. Journal of Reproductive Medicine and Embryology 0, 0–0 (2024).
  27. 27. Vannuccini, S. et al. Menstrual Distress Questionnaire (MEDI-Q): a new tool to assess menstruation-related distress. Reproductive BioMedicine Online 43, 1107–1116 (2021).
  28. 28. Cassioli, E. et al. The menstrual distress questionnaire (MEDI-Q): reliability and validity of the English version. Gynecological Endocrinology 39, 2227275 (2023).
  29. 29. Chapron, C. et al. A new validated screening method for endometriosis diagnosis based on patient questionnaires. eClinicalMedicine 44, 101263 (2022).
  30. 30. Guerriero, S. et al. Systematic approach to sonographic evaluation of the pelvis in women with suspected endometriosis, including terms, definitions and measurements: a consensus opinion from the International Deep Endometriosis Analysis (IDEA) group. Ultrasound Obstet Gynecol 48, 318–332 (2016).
  31. 31. Bazot, M. & Daraï, E. Diagnosis of deep endometriosis: clinical examination, ultrasonography, magnetic resonance imaging, and other techniques. Fertility and Sterility 108, 886–894 (2017).
  32. 32. Petraglia, F., Vannuccini, S., Santulli, P., Marcellin, L. & Chapron, C. An update for endometriosis management: a position statement. Journal of Endometriosis and Uterine Disorders 6, 100062 (2024).
  33. 33. Capezzuoli, T., Rossi, M., La Torre, F., Vannuccini, S. & Petraglia, F. Hormonal drugs for the treatment of endometriosis. Current Opinion in Pharmacology 67, 102311 (2022).
  34. 34. De Ziegler, D., Borghese, B. & Chapron, C. Endometriosis and infertility: pathophysiology and management. The Lancet 376, 730–738 (2010).
  35. 35. Vannuccini, S. et al. Pathogenesis of adenomyosis: an update on molecular mechanisms. Reproductive BioMedicine Online 35, 592–601 (2017).
  36. 36. Zhai, J., Vannuccini, S., Petraglia, F. & Giudice, L. C. Adenomyosis: Mechanisms and Pathogenesis. Semin Reprod Med 38, 129–143 (2020).
  37. 37. Chapron, C. et al. Diagnosing adenomyosis: an integrated clinical and imaging approach. Human Reproduction Update 26, 392–411 (2020).
  38. 38. Vannuccini, S. & Petraglia, F. Adenomyosis: is an endocrine-related uterine dysfunction? Gynecological Endocrinology 38, 1017–1018 (2022).
  39. 39. Struble, J., Reid, S. & Bedaiwy, M. A. Adenomyosis: A Clinical Review of a Challenging Gynecologic Condition. Journal of Minimally Invasive Gynecology 23, 164–185 (2016).
  40. 40. Bulun, S. E., Yildiz, S., Adli, M. & Wei, J.-J. Adenomyosis pathogenesis: insights from next-generation sequencing. Human Reproduction Update 27, 1086–1097 (2021).
  41. 41. Vannuccini, S., Jain, V., Critchley, H. & Petraglia, F. From menarche to menopause, heavy menstrual bleeding is the underrated compass in reproductive health. Fertility and Sterility 118, 625–636 (2022).
  42. 42. Vannuccini, S. & Petraglia, F. Recent advances in understanding and managing adenomyosis. F1000Res 8, 283 (2019).
  43. 43. Van Den Bosch, T. et al. Terms, definitions and measurements to describe sonographic features of myometrium and uterine masses: a consensus opinion from the Morphological Uterus Sonographic Assessment (MUSA) group. Ultrasound Obstet Gynecol 46, 284–298 (2015).
  44. 44. Vannuccini, S., Luisi, S., Tosti, C., Sorbi, F. & Petraglia, F. Role of medical therapy in the management of uterine adenomyosis. Fertility and Sterility 109, 398–405 (2018).
  45. 45. Petraglia, F. Uterine fibroid: from pathogenesis to clinical management. Best Practice & Research Clinical Obstetrics & Gynaecology 34, 1–2 (2016).
  46. 46. Vannuccini, S. et al. Uterine Fibroids, Perceived Stress, and Menstrual Distress: a Key Role of Heavy Menstrual Bleeding. Reprod. Sci. 30, 1608–1615 (2023).
  47. 47. Munro, M. G., Critchley, H. O. D., Fraser, I. S., & the FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Intl J Gynecology & Obste 143, 393–408 (2018).
  48. 48. Pavone, D., Clemenza, S., Sorbi, F., Fambrini, M. & Petraglia, F. Epidemiology and Risk Factors of Uterine Fibroids. Best Practice & Research Clinical Obstetrics & Gynaecology 46, 3–11 (2018).
  49. 49. Uterine Fibroids: A Clinical Casebook. (Springer International Publishing : Imprint : Springer, Cham, 2018).
  50. 50. Capezzuoli, T. et al. Recurrence of Uterine Fibroids After Conservative Surgery or Radiological Procedures: a Narrative Review. Reprod. Sci. (2023) doi:10.1007/s43032-023-01418-2.
  51. 51. Donnez, J. & Dolmans, M.-M. Uterine fibroid management: from the present to the future. Hum. Reprod. Update 22, 665–686 (2016).
Retrieved from ‘https://journal.topitalianscientists.org/index.php?title=Uterine_disorders_in_reproductive_life&oldid=1315’